Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
2021 08 13T134838Z 1 LYNXMPEH7C0SE RTROPTP 4 HEALTH CORONAVIRUS USA VACCINE - Business Express
FILE PHOTO: A syringe is filled with a dose of Pfizer's coronavirus disease (COVID-19) vaccine at a pop-up community vaccination center at the Gateway World Christian Center in Valley Stream, New York, U.S., February 23, 2021. REUTERS/Brendan McDermid/File Photo

U.S. FDA authorizes COVID-19 vaccine boosters for the immunocompromised


By Manas Mishra and Michael Erman

(Reuters) -The U.S. Food and Drug Administration has authorized a third dose of COVID-19 vaccines by Pfizer Inc-BioNTech and Moderna Inc for people with compromised immune systems.

The amended https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised emergency use authorization on Thursday paves the way for people who have had an organ transplant, or those with a similar level of weakened immune system, to get an extra dose. The patients may consult with their doctor to see if they are eligible, FDA spokesperson Abby Capobianco said.

“After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines,” Janet Woodcock, U.S. FDA’s acting commissioner, said in a tweet https://twitter.com/DrWoodcockFDA/status/1426019820445868033 on Thursday.

“Others who are fully vaccinated are adequately protected & do not need an additional dose of COVID-19 vaccine at this time.”

The vulnerable group makes up less than 3% of U.S. adults, Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), had said before the authorization.

Supporting the move to approve an additional shot, Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, said it would be important for the CDC to provide clear recommendations about who should receive it.

“Most clinicians are not going to know what an equivalent level of compromise is for solid organ transplant patients… hopefully the CDC will be more specific about that… (and) whether or not therapies can be manipulated so you can give your patient an optimal chance of having an immune response.”

A panel of advisers to the CDC will meet on Friday to discuss booster doses, and a vote later by the committee will help decide on the rollout of the extra shots.

BOOSTERS FOR YOUNG, HEALTHY

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

Scientists are still divided over the broad use of COVID-19 vaccine boosters among those without underlying problems as benefits of the boosters remain undetermined.

Pfizer has said the efficacy of the vaccine it developed with partner BioNTech drops over time, citing a study that showed 84% effectiveness from a peak of 96% four months after a second dose.

Moderna has also said it sees the eventual need for booster doses, especially since the Delta variant has caused “breakthrough” infections in fully vaccinated people.

Reports of infections among vaccinated people and concerns about diminishing protection have galvanized wealthy nations to distribute booster shots, even as many countries struggle to access first vaccine doses.

The World Health Organization last week called for a moratorium on COVID-19 vaccine booster shots until at least the end of September.

“We think other countries might also follow suite, despite WHO’s concerns for vaccine equity, due to the rising health risks posed by the Delta variant and diminishing protection of the vaccine over time,” CFRA Research analyst Sel Hardy said.

Wall Street analysts expect the authorization of a booster dose for a broad population to bolster profits of COVID-19 vaccine makers.

Shares of Pfizer, Moderna and U.S.-listed shares of BioNTech rose between 1% and 2% in early trading.

(Reporting by Manas Mishra in Bengaluru; Additional reporting by Bhargav Acharya; Editing by Shounak Dasgupta and Shinjini Ganguli)

Recent Post: